Immunologic Mechanisms for Heterogeneity of Cutaneous Lupus Erythematosus
Abstract
Approximately 50 percent of patients with discoid lupus erythematosus (DLE) respond to antimalarials, the primary first-line therapy for DLE. Because of a two-month delay in onset of action of antimalarials, however, the other half of these patients continue with disease activity and progressive scarring, only to find they are not responding. Antimalarials treatment includes hydroxychloroquine (HCQ), yet not all patients respond to hydroxychloroquine (HCQ), quinacrine (QC), and many are refractory to antimalarials(NR). Our group has previously shown that QC responders demonstrate increased conventional dendritic cells (cDC) and TNFalpha relative to HCQ responders. We proposed to investigate the differences between these patients using imaging mass cytometry(IMC), an unbiased multiplexed technique. The molecular and cellular basis for this heterogeneity of responses to treatment remains uncharacterized, leading to treatment delays and then the use of toxic therapies and multiple therapeutic regimens. Our goal is to understand the biologic determinants in newly diagnosed DLE patients who then do not respond to antimalarials. We hypothesize that, before treatment, antimalarial non-responders will have differentially expressed T cell subsets and unique pathway markers relative to antimalarial responders.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1225475
Entities
People
- Victoria Werth